Patent Royalty

A patent royalty is the consideration paid for the right to make, use, or sell a patented invention: DEFINITION: a royalty is the price of a license — the compensation the patent owner receives in exchange for granting the licensee rights under the patent; without a license, making, using, or selling a patented invention constitutes infringement; FORMS OF PATENT ROYALTIES: (a) RUNNING ROYALTY: most common form; calculated as a percentage of the licensee's net sales of licensed products; or a fixed dollar amount per unit sold; advantages: aligns licensor's income with licensee's commercial success; disadvantages: requires ongoing royalty reports and audit rights; (b) LUMP SUM: single upfront payment covering the entire license period; common in settlements; near-expiration patent deals; cross-license balancing payments; advantages: immediate payment; no reporting overhead; disadvantages: licensor misses out on higher-than-projected sales; (c) MILESTONE ROYALTY: payments triggered by specific events: regulatory approval (FDA clearance); sales thresholds (first $10M in revenue); technology benchmarks (product enters production); common in biotech/pharma licensing; (d) MINIMUM ANNUAL ROYALTY (MAR): contractual floor on annual royalties; if running royalties fall below the minimum, the licensee must pay the minimum regardless; protects the licensor from negligible commercialization; (e) HYBRID: combination of upfront lump sum + running royalty; the upfront payment may be structured as an advance against future royalties; common when the licensor needs immediate capital but wants ongoing upside; (f) PER-USE OR SUBSCRIPTION: royalty tied to number of uses, API calls, or subscription fees; common in software and SaaS licensing.

When a patent is infringed and the patent owner seeks damages, courts calculate the reasonable royalty using a hypothetical negotiation framework: 35 U.S.C. § 284: damages shall be adequate to compensate for infringement, but in no event less than a reasonable royalty for the use made of the invention; HYPOTHETICAL NEGOTIATION: the court imagines a negotiation between a willing licensor and willing licensee at the time infringement began; Panduit Corp. v. Stahlin Bros. Fibre Works (6th Cir. 1978): reasonable royalty is the minimum floor of damages; GEORGIA-PACIFIC FRAMEWORK (15 FACTORS): Georgia-Pacific Corp. v. United States Plywood Corp. (S.D.N.Y. 1970): the 15-factor framework used to calculate the hypothetical negotiation rate; KEY FACTORS: Factor 1: royalties received for licensing the patent; Factor 2: rates paid for comparable patents; Factor 3: nature and scope of the license (exclusive vs. non-exclusive; limited fields); Factor 4: licensor's established policy and marketing programs; Factor 6: effect of selling the licensed product on the licensor's business; Factor 8: established profitability of the product; Factor 9: utility and advantages of the patented property over the prior art; Factor 11: extent to which infringer used the invention and commercial success; Factor 13: portion of realizable profit attributable to the patent; Factor 15: the royalty agreed upon by a willing licensor and licensee; THE APPORTIONMENT PRINCIPLE: for complex products (smartphones, computers, medical devices), the royalty must be apportioned to the value of the patented contribution; LaserDynamics v. Quanta Computer (Fed. Cir. 2012): royalty base must be the smallest salable patent-practicing unit (SSPPU); EMVR exception applies only when the patent drives customer demand for the entire product.

Patent royalty rates vary significantly by industry, technology type, and license structure: INDUSTRY BENCHMARK RANGES (APPROXIMATE): PHARMACEUTICAL/BIOTECH: drug compound patents: 5-25% of net sales; earlier-stage compound (pre-Phase II): lower rate; approved drug: higher rate; biotech platforms and research tools: 1-5%; diagnostic patents: 3-8%; MEDICAL DEVICES: breakthrough devices: 5-15%; incremental improvements: 2-7%; combination products: 3-10%; SOFTWARE/INTERNET: core platform patents: 2-8%; standard-essential patents (per FRAND): typically well below 1% of device price; enterprise software features: 1-5%; SEMICONDUCTOR/ELECTRONICS: core semiconductor process patents: 1-5%; consumer electronics features: 0.5-2%; FRAND-committed SEPs: aggregate for entire standard typically 1-5% of device price; MECHANICAL/INDUSTRIAL: industrial equipment: 1-5%; specialized manufacturing processes: 2-8%; consumer products: 1-4%; AUTOMOTIVE: mechanical/safety features: 1-5%; automotive SEPs (5G connectivity, V2X): subject to FRAND negotiations; MATERIALS/CHEMISTRY: specialty materials: 2-8%; commodity materials: 1-3%; IMPORTANT CAVEATS: industry ranges are starting points, not formulas; the actual rate depends on: (a) the strength and breadth of the specific patent claims; (b) the commercial importance of the patented feature to the product; (c) available design-around alternatives; (d) the licensor's licensing history; (e) whether the licensee is a direct competitor; royalty stacking (multiple patents covering the same product) tends to push individual rates lower; THE 25% RULE: popular heuristic (25% of licensee's profit to licensor); Federal Circuit EXCLUDED it in Uniloc USA v. Microsoft (Fed. Cir. 2011): no basis in scientific study; cannot be used as a starting point without independent evidence.

The royalty base is as important as the royalty rate — together they determine the total royalty payment: ROYALTY BASE BASICS: royalty base = the revenue figure to which the royalty rate is applied; royalty due = royalty rate × royalty base; NET SALES DEFINITION: most patent licenses define royalty base as net sales (gross revenue minus returns, trade discounts, freight, and applicable taxes); ENTIRE MARKET VALUE RULE (EMVR): the royalty base may be the entire product if the patent drives demand for the entire product; EMVR is a NARROW EXCEPTION — rarely applicable in modern patent damages cases; Federal Circuit has repeatedly cabined EMVR: Lucent Technologies v. Gateway (Fed. Cir. 2009); LaserDynamics v. Quanta (Fed. Cir. 2012); SMALLEST SALABLE PATENT-PRACTICING UNIT (SSPPU): the default royalty base should be the smallest commercially available component that incorporates the patented feature; in smartphones: the Wi-Fi chip (not the phone) for a Wi-Fi patent; in medical devices: the specific component containing the patented mechanism; APPORTIONMENT BEYOND SSPPU: even the SSPPU may contain multiple patented features; additional apportionment may be required: divide the SSPPU revenue by the number of separately-patented features; or use a technical survey to determine what portion of the SSPPU's value comes from the patented feature; NEGOTIATED vs. LITIGATED: in voluntary licenses, parties can freely agree on any royalty base; a higher royalty base is often paired with a lower royalty rate (economic equivalence); courts apply stricter apportionment analysis than voluntary license parties; STRATEGIC DRAFTING: when using a higher royalty base in a negotiated license, document the parties' understanding that the high base was chosen for convenience and paired with an appropriately reduced rate; this prevents litigation-style reinterpretation.

Royalty audit provisions are a critical operational protection for patent owners in running royalty arrangements: PURPOSE OF AUDIT RIGHTS: running royalties require the licensee to self-report sales; licensees may (intentionally or accidentally): undercount units; exclude certain products from the royalty base; classify infringing products as non-royalty-bearing; use overly broad deductions from gross to net sales; audit rights allow the licensor to verify the accuracy of royalty reports; STANDARD AUDIT PROVISION TERMS: FREQUENCY: typically once per calendar year (or once per 12-month period); NOTICE: 30-60 days advance written notice required; AUDITOR: independent certified public accountant (CPA) designated by the licensor; SCOPE: access to books and records: sales records; invoices; manufacturing records; royalty calculation worksheets; CONFIDENTIALITY: audit results are confidential to both parties; covered by the license's confidentiality provisions; COST ALLOCATION: licensor pays audit costs if underpayment is less than the agreed threshold (typically 5-10% of royalties owed for the period); licensee pays audit costs if underpayment exceeds the threshold; WHAT AUDITORS LOOK FOR: products not included in the royalty base; geographic territories excluded; deductions from gross sales that exceed contractual definitions; sublicensee royalties not passed through; DISPUTE RESOLUTION: if the parties dispute the audit findings: a second audit by a mutually agreed CPA; binding arbitration; STATUTES OF LIMITATIONS: most licenses include a royalty report finality provision: after 3 years (or the agreed period), royalty reports are deemed final and cannot be challenged; COMMON FINDINGS IN ROYALTY AUDITS: according to audit firm surveys, 20-40% of audits find material underpayments; most common: geographic exclusions; product classification errors; improper deduction methodology.